KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Total Liabilities (2016 - 2025)

Eli Lilly (LLY) has disclosed Total Liabilities for 17 consecutive years, with $85.9 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities rose 33.36% year-over-year to $85.9 billion, compared with a TTM value of $85.9 billion through Dec 2025, up 33.36%, and an annual FY2025 reading of $85.9 billion, up 33.36% over the prior year.
  • Total Liabilities was $85.9 billion for Q4 2025 at Eli Lilly, down from $91.1 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $101.0 billion in Q2 2025 and bottomed at $46.3 billion in Q1 2022.
  • Average Total Liabilities over 5 years is $62.8 billion, with a median of $54.9 billion recorded in 2023.
  • The sharpest move saw Total Liabilities dropped 6.95% in 2024, then skyrocketed 72.79% in 2025.
  • Year by year, Total Liabilities stood at $48.8 billion in 2021, then rose by 0.19% to $48.9 billion in 2022, then soared by 39.75% to $68.3 billion in 2023, then fell by 5.69% to $64.4 billion in 2024, then soared by 33.36% to $85.9 billion in 2025.
  • Business Quant data shows Total Liabilities for LLY at $85.9 billion in Q4 2025, $91.1 billion in Q3 2025, and $101.0 billion in Q2 2025.